| Literature DB >> 24591765 |
Krzysztof Gawrychowski1, Grzegorz Szewczyk2, Ewa Skopińska-Różewska3, Maciej Małecki4, Ewa Barcz5, Paweł Kamiński5, Magdalena Miedzińska-Maciejewska6, Wacław Śmiertka7, Dariusz Szukiewicz8, Piotr Skopiński9.
Abstract
Ovarian cancer cells are able to create invasive implants in the peritoneum and their growth is directly associated with the angiogenetic potential. This effect is probably stimulated by vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8), which are both found in ascites. The aim of this study was to assess the influence of ascites produced by ovarian cancer on the angiogenesis. Peritoneal fluid was collected from patients with advanced ovarian cancer; cancer cells were separated from CD45+ leukocytes. Angiogenesis was assessed in mice, after intradermal injection of full cellular suspension together with supernatant or phosphate buffered saline, purified cancer cells suspension, or CD45+ leukocytes suspension. The angiogenesis index (AI) was assessed after 72 hours. VEGF and Il-8 were measured in the supernatant and cellular suspension. AI was the highest in the isolated cancer cells suspensions as well in the group stimulated with supernatant. Both VEGF and IL-8 were high in supernatants from ascites rich in cancer cells (>45%). A significant correlation was revealed between IL-8 concentration and AI. We conclude that ascites in patients with advanced ovarian cancer stimulates angiogenesis and this mechanism is dependent mostly on cancer cells activity and enhanced by cooperation with infiltrating leukocytes.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24591765 PMCID: PMC3925613 DOI: 10.1155/2014/683757
Source DB: PubMed Journal: Dis Markers ISSN: 0278-0240 Impact factor: 3.434
Demographic characteristic of patients.
| Age | Range 41–96 | Mean 59 |
|---|---|---|
| Staging FIGO | IIc–IV | |
|
| ||
| Histology | Serous adenocarcinoma |
|
| Mucinous adenocarcinoma |
| |
| Clear cell carcinoma |
| |
| Endometrial carcinoma |
| |
|
| ||
| Surgical treatment | Optimal cytoreduction |
|
| Residual disease |
| |
|
| ||
| Chemotherapy treatment (any before the fluid collection) | Yes |
|
| No |
| |
|
| ||
| Chemotherapy treatment in the last 4 weeks | Yes |
|
| No |
| |
Figure 1The angiogenetic index was assessed in murine skin after injection with full cellular suspension (Full) and in the subgroup with low (<45%) and high (>45%) percentage of cancer cells (Low), (High), respectively, after injection with separated cancer cells (Cancer Cells) and CD45 positive leukocytes (CD45+). The bars represent mean number of newly formed vessels ±SD. Differences between all groups were tested with ANOVA and were deemed statistically significant.
VEGF and IL-8 concentration determined in supernatant and homogenized cells suspension separated from peritoneal fluid.
| Supernatant | Homogenized cells suspension | |||||
|---|---|---|---|---|---|---|
| Group L | Group H |
| Group L | Group H |
| |
| VEGF (pg/mL) | 8931 ± 2245 | 21851 ± 5798 | 0.035 | 5456 ± 1342 | 9375 ± 3565 | 0.08 |
| IL-8 (pg/mL) | 992 ± 103 | 2793 ± 230 | 0.00043 | 571 ± 140 | 40047 ± 13123 | 0.0085 |
Group L: low percentage of cancer cells (<45%); group H: high percentage of cancer cells (>45%). The groups were compared with student's t-test and deemed statistically significant if P < 0.05.
The correlation indices between angiogenesis index (mean number of newly formed vessels) and VEGF and IL-8 concentration determined in supernatant separated from peritoneal fluid. Description: treatment means any chemotherapy received less than 4 weeks before fluid collection and no treatment means no chemotherapy or chemotherapy received more than 4 weeks before fluid collection. The correlation indices were estimated with Pearson's test; results statistically significant are in bold.
| VEGF | IL-8 | |||
|---|---|---|---|---|
| Treatment | No treatment | Treatment | No treatment | |
| Angiogenesis index |
|
|
|
|